Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro (original) (raw)
Fauci, A. S. et al. HIV vaccine research: the way forward. Science321, 530–532 (2008). ArticleCAS Google Scholar
Davey, R. T. Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA96, 15109–15114 (1999). ArticleCAS Google Scholar
Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Discov.2, 624–634 (2003). ArticleCAS Google Scholar
Mills, E. J. et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med.3, 2039–2064 (2006). Google Scholar
Bangsberg, D. R. et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS17, 1925–1932 (2003). Article Google Scholar
Ruff, C. T. et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J. Virol.76, 9481–9492 (2002). ArticleCAS Google Scholar
Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol.80, 6441–6457 (2006). ArticleCAS Google Scholar
Dinoso, J. B. et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA160, 9403–9408 (2009). Article Google Scholar
Coiras, M., Lopez-Huertas, M. R., Perez-Olmeda, M. & Alcami, J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Rev.7, 798–812 (2009). CAS Google Scholar
Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med.5, 512–517 (1999). ArticleCAS Google Scholar
Richman, D. D. et al. The challenge of finding a cure for HIV infection. Science323, 1304–1307 (2009). ArticleCAS Google Scholar
Stellbrink, H-J. et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS16, 1479–1487 (2002). ArticleCAS Google Scholar
Van Praag, R. M. E. et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD41 T cell depletion. J. Clin. Immunol.21, 218–226 (2001). ArticleCAS Google Scholar
Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood98, 3006–3015 (2001). ArticleCAS Google Scholar
Korin, Y. D., Brooks, D. G., Brown, S., Korotzer, A. & Zack, J. A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol.76, 8118–8123 (2002). ArticleCAS Google Scholar
Brow, S. J. & Hezarah, M. Methods of administering prostratin and structural analogs thereof. US patent no. 2009126949 (2009).
Wender, P. A., Kee, J-M. & Warrington, J. M. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science320, 649–652 (2008). ArticleCAS Google Scholar
Pettit, G. R. et al. Isolation and structure of bryostatin 1. J. Am. Chem. Soc.104, 6846–6848 (1982). ArticleCAS Google Scholar
Kortmansky, J. & Schwartz, G. K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest.21, 924–936 (2003). ArticleCAS Google Scholar
Hale, K. J., Hummersone, M. G., Manaviazar, S. & Frigerio, M. The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep.19, 413–453 (2002). ArticleCAS Google Scholar
Etcheberrigaray, R. et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl Acad. Sci. USA101, 11141–11146 (2004). ArticleCAS Google Scholar
Kinter, A. L., Poli, G., Maury, W., Folks, T. M. & Fauci, A. S. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol.64, 4306–4312 (1990). CASPubMedPubMed Central Google Scholar
Quatsha, K. A., Rudolph, C., Marme, D., Schachtele, C. & May, W. S. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl Acad. Sci. USA90, 4674–4676 (1993). Article Google Scholar
Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One5, e11160 (2010). Article Google Scholar
Barr, P. M. et al. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol.84, 484–487 (2009). ArticleCAS Google Scholar
Schaufelberger, D. E. et al. The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J. Nat. Prod.54, 1265–1270 (1991). ArticleCAS Google Scholar
Trindade-Silva, A. E., Lim-Fong, G. E., Sharp, K. H. & Haygood, M. G. Bryostatins: biological context and biotechnological prospects. Curr. Opin. Biotechnol.21, 834–842 (2010). ArticleCAS Google Scholar
Kageyama, M. et al. Synthesis of bryostatin 7. J. Am. Chem. Soc.112, 7407–7408 (1990). ArticleCAS Google Scholar
Evans, D. A. et al. Total synthesis of bryostatin 2. J. Am. Chem. Soc.121, 7540–7552 (1999). ArticleCAS Google Scholar
Ohmori, K. et al. Total synthesis of bryostatin 3. Angew. Chem. Int. Ed.39, 2290–2294 (2000). ArticleCAS Google Scholar
Trost, B. M. & Dong, G. Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature456, 485–488 (2008). ArticleCAS Google Scholar
Keck, G. E., Poudel, Y. B., Cummins, T. J., Rudra, A. & Covel, J. A. Total synthesis of bryostatin 1. J. Am. Chem. Soc.133, 744–747 (2011). ArticleCAS Google Scholar
Wender, P. A. & Schrier, A. J. Total synthesis of bryostatin 9. J. Am. Chem. Soc.133, 9228–9231 (2011). ArticleCAS Google Scholar
Lu, Y., Woo, S. & Krische, M. J. Total synthesis of bryostatin 7 via C–C bond-forming hydrogenation. J. Am. Chem. Soc.133, 13876–13879 (2011). ArticleCAS Google Scholar
Wender, P. A. et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc. Natl Acad. Sci. USA85, 7197–7201 (1988). ArticleCAS Google Scholar
Wender, P. A. in Drug Discovery Research: New Frontiers in the Post-Genomic Era (ed. Huang, Z.) Ch. 6 (Wiley-VCH, 2007).
Wender, P. A., Loy, B. A. & Schrier, A. J. Translating nature's library: the bryostatins and function-oriented synthesis. Isr. J. Chem.51, 453–472 (2011). ArticleCAS Google Scholar
Wender, P. A., Verma, V. A., Paxton, T. J. & Pillow, T. H. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res.41, 40–49 (2008). ArticleCAS Google Scholar
Wender, P. A. et al. Synthesis of the first members of a new class of biologically active bryostatin analogues. J. Am. Chem. Soc.120, 4534–4535 (1998). ArticleCAS Google Scholar
Wender, P. A. et al. The practical synthesis of a novel and highly potent analogue of bryostatin. J. Am. Chem. Soc.124, 13648–13649 (2002). ArticleCAS Google Scholar
Wender, P. A., DeChristopher, B. A. & Schrier, A. J. Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy. J. Am. Chem. Soc.130, 6658–6659 (2008). ArticleCAS Google Scholar
Wender, P. A. et al. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc. Natl Acad. Sci. USA108, 6721–6726 (2011). ArticleCAS Google Scholar
Mackay, H. J. & Twelves, C. J. Targeting the protein kinase C family: are we there yet? Nature Rev. Cancer7, 554–562 (2007). ArticleCAS Google Scholar
DeChristopher, B. A., Fan, A. C., Felsher, D. W. & Wender, P. A. ‘Picolog’, a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget3, 58–66 (2012). Article Google Scholar
Khan, T. K., Nelson, T. J., Verma, V. A., Wender, P. A. & Alkon, D. L. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts. Neurobiol. Dis.34, 332–339 (2009). ArticleCAS Google Scholar
Crane, E. A. & Scheidt, K. A. Prins-type macrocyclizations as an efficient ring-closing strategy in natural product synthesis. Angew. Chem. Int. Ed.49, 8316–8326 (2010). ArticleCAS Google Scholar
Krasovskiy, A., Kopp, F. & Knochel, P. Soluble lanthanide salts (LnCl3·2LiCl) for the improved addition of organomagnesium reagents to carbonyl compounds. Angew. Chem. Int. Ed.45, 497–500 (2006). ArticleCAS Google Scholar
Marsden, M. D. & Zack, J. A. Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virol.5, 97–109 (2010). ArticleCAS Google Scholar
Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection in T cells in vitro. EMBO J.22, 1868–1877 (2003). ArticleCAS Google Scholar
Williams, S. A. et al. Prostratin antagonizes HIV latency by activating NF-κB. J. Biol. Chem.279, 42008–42017 (2004). ArticleCAS Google Scholar
Kovochich, M., Marsden, M. D. & Zack, J. A. Activation of latent HIV using drug-loaded nanoparticles. PLoS One6, e18270 (2011). ArticleCAS Google Scholar
Brooks, D. G. et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity19, 413–423 (2003). ArticleCAS Google Scholar